Skip to main content

Across our company, we combine innovative technologies with leading science to deliver care in groundbreaking new ways, from early-stage innovation to commercialization.

External innovation and collaboration

Johnson & Johnson Innovation is comprised of dedicated teams of scientists, entrepreneurs, and investors, whose mission is to find and accelerate the most promising early discoveries that could transform human health. With approximately 50 percent of the J&J Innovative Medicine pipeline being derived through external collaborations and with J&J MedTech’s new investments in cardiovascular disease, our innovation partnering model supports pharmaceuticals and medtech entrepreneurs at any stage of their development, with personalized attention and capabilities including access to incubation and acceleration through JLABS, collaborations and deal-making through our Innovation Centers, equity investment through our investment fund (JJDC), business development for mid- and late-stage opportunities and our expertise and mentoring from our global network.

William N. Hait, M.D., Ph.D., Executive Vice President, Chief External Innovation and Medical Officer, Johnson & Johnson (photo)

We bring together outstanding teams to tackle the world’s toughest health challenges. The ideas of today could be the therapies or medical technologies of tomorrow, and we’re all-in for the journey, unlocking those ideas wherever they originate.”

William N. Hait, M.D., Ph.D., Executive Vice President, Chief External Innovation and Medical Officer, Johnson & Johnson

As a convener and accelerator of innovation around the world, J&J-Innovation incorporates diversity, equity, and inclusion initiatives into our programming to support, upskill and enable collaborators throughout the ecosystem to champion and accelerate health equity. Through our global incubator networks, we provide early-stage innovators with access to funding, resources, expertise and industry connections to accelerate the time it takes for life science and health technology innovations to reach patients. J&J QuickFire Challenges are competitions that advance potential breakthrough ideas from innovators across the globe. Awardees are provided financial support and access to the global JLABS network. In 2023, a total of $350,000 was deployed in grant funding to support challenges focused on health equity.

The J&J-Innovation Health Equity Assessment Tool (HEAT) helps innovators in our network and beyond to benchmark and track their own impact on health equity. To date, more than 60 current and alumni JLABS companies have used the tool.

In 2023, the first cohort graduated from our external Board Fellows Program that we launched to help diverse non-J&J senior executives prepare for Board leadership roles in the healthcare industry. Two fellows have already received a Board appointment at external companies.

Through JLABS, J&J-Innovation continues to collaborate with the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. on BLUE KNIGHT™, a multi-year joint initiative that currently supports more than 40 companies dedicated to anticipating potential health security threats and developing innovative countermeasures. One of these companies is BioCold Technologies (NanoFreeze), that develops technology to improve vaccine accessibility in rural communities using technology capable of freezing at higher temperatures and for longer periods without requiring constant energy consumption. The global BLUE KNIGHT™ portfolio of current and alumni resident companies is 56% female-led and 56% minority-led.

Our corporate venture group, JJDC, supports a portfolio of more than 100 companies, having invested more than $3.5 billion in capital since 2014. The fund maintains a proactive approach to driving innovation.

Johnson & Johnson Innovation—JJDC, Inc.
Johnson & Johnson Innovation—JLABS